Table 3.
Major clinical trials of neoantigen vaccines in CRC.
| NCT Number (status) | Tumor | Interventions | Adjuvant/combined therapy | Phases (Enrollment) | Completion Date |
|---|---|---|---|---|---|
| NCT05141721 (Not yet recruiting) | mCRC | GRT-C901, GRT-R902 | Fluoropyrimidine, oxaliplatin, bevacizumab, ipilimumab | Phase II/III (665) | March 2027 |
| NCT03639714 (Active, not recruiting) | MSS solid tumors include CRC | GRT-C901, GRT-R902 | Nivolumab, Ipilimumab | Phase I/II (214) | March 2023 |
| NCT03953235 (Recruiting) | MSS solid tumors include CRC | GRT-C903,GRT-R904 | Nivolumab, Ipilimumab | Phase I/II (144) | December 2023 |
| NCT04912765 (Recruiting) | mCRC, hepatocellular cancer | Neoantigen Dendritic Cell Vaccine | Nivolumab | Phase II (60) | May 2025 |
| NCT05243862 (Not yet recruiting) | mCRC | PolyPEPI1018 | Montanide ISA 51, Atezolizumab | Phase II (28) | March 2026 |
| NCT05078866 (Not yet recruiting) | Lynch Syndrome | GAd-209-FSP, MVA-209-FSP | / | Phase Ib/II (45) | December 2025 |
| NCT01885702 (Active, not recruiting) | Colorectal Cancer (MSI) or Lynch syndrome | DC vaccination | / | Phase I/II (25) | December 2022 |
| NCT05130060 (Recruiting) | mCRC | PolyPEPI1018 | Montanide ISA 51, TAS-102 | Phase I (15) | May 2024 |
| NCT04117087 (Recruiting) | MSS mCRC, Pancreatic Cancer | KRAS peptide vaccine | Poly-ICLC / nivolumab, ipilimumab. | Phase I (30) | June 2024 |
| NCT04853017 (Recruiting) | KRAS/NRAS mutated (G12D or G12R) solid tumor (including CRC) | ELI-002 2P | Amph-CpG-7909 | Phase I (18) | September 2024 |
| NCT04147078 (Recruiting) | Solid tumors including CRC | Neoantigen-primed DC Vaccine | / | Phase I (80) | June 2023 |
| NCT04799431 (Not yet recruiting) | mCRC, metastatic pancreatic cancer | Neoantigen Vaccine | Poly-ICLC/ Retifanlimab | Phase I (12) | February 2026 |
mCRC, metastatic colorectal cancer; MSS, microsatellite stable; pMMR, proficient mismatch repair.